Needham analyst David Saxon has maintained their neutral stance on STAA stock, giving a Hold rating today.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
David Saxon has given his Hold rating due to a combination of factors surrounding Staar Surgical’s recent performance and strategic moves. The company’s first-quarter revenue for 2025 exceeded expectations, largely due to strong sales in the Asia-Pacific region excluding China. Despite this positive outcome, the company withdrew its 2025 guidance, although management remains optimistic about achieving their previous revenue range of $240-300 million.
Additionally, Staar Surgical has taken proactive measures to mitigate potential tariff impacts by shipping consigned inventory into China, which is expected to meet demand until early 2026. By that time, the company plans to have increased production capacity at its Swiss facility to continue supplying the Chinese market. Given these circumstances, Saxon views the risk and reward balance as justifying a Hold rating.
In another report released today, Piper Sandler also maintained a Hold rating on the stock with a $16.00 price target.